BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
IPO Year: 2019
Exchange: NASDAQ
Website: biontech.de
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/7/2024 | $95.00 | Hold → Buy | Deutsche Bank |
8/2/2024 | Hold → Buy | HSBC Securities | |
5/14/2024 | $100.00 | In-line | Evercore ISI |
2/23/2024 | $127.00 | Outperform | BMO Capital Markets |
1/5/2024 | Perform | Oppenheimer | |
12/1/2023 | $106.00 → $99.00 | Neutral → Underweight | JP Morgan |
10/16/2023 | $124.00 → $111.00 | Buy → Hold | HSBC Securities |
7/14/2023 | $124.00 | Buy | HSBC Securities |
5/17/2023 | $165.00 → $170.00 | Neutral → Buy | Redburn |
12/15/2022 | $239.00 | Neutral → Buy | BofA Securities |
Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024. She will join BioNTech from Novartis AG ("Novartis") and succeed Sean Marett in this role. Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access. In her new role, she will drive and execute the global commercialization strategy to leverage BioNTech's full potential as a verticall
MAINZ, Germany, December 12, 2023 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) will inaugurate its first African site in Kigali, Rwanda, on Monday, December 18th, 2023. The inauguration takes place on the occasion of the set-up of the containers for the first manufacturing unit called BioNTainer. BioNTech invites media and the general public to join a live stream of the event on the same day at 2:00 pm CET. The statements of high-level dignitaries including official government representatives as well as members of BioNTech's board will be broadcasted in addition to the ceremonial ribbon cutting. The live stream will be available via this link, which will
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
SC 13D - BioNTech SE (0001776985) (Filed by)
SC 13G/A - BioNTech SE (0001776985) (Subject)
SC 13G/A - BioNTech SE (0001776985) (Subject)
SC 13G/A - BioNTech SE (0001776985) (Subject)
SC 13G/A - BioNTech SE (0001776985) (Subject)
SC 13G/A - BioNTech SE (0001776985) (Subject)
SC 13G/A - BioNTech SE (0001776985) (Subject)
SC 13G/A - BioNTech SE (0001776985) (Subject)
The European Commission faced criticism from Europe’s second-highest court regarding transparency issues surrounding COVID-19 vaccine contracts from four years ago. This scrutiny comes on the eve of a crucial vote on Commission head Ursula von der Leyen‘s reelection bid. Some European lawmakers have been vocal about their dissatisfaction with how the Commission handled its multibillion-euro contracts, particularly its failure to disclose text messages between von der Leyen and Pfizer Inc (NYSE:PFE) CEO Albert Bourla regarding one of the agreements. In 2022, a Pfizer executive “categorically” ruled out that the pharma giant’s chief executive agreed on the European COVID-19 contract v
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent litigation UK trial on validity of intellectual property rights EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A tail technology) began July 10; judgement expected later in 2024
Wednesday, GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) announced they have restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investment and focus on its respective mRNA development activities. Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases. Through this collaboration, GSK and CureVac have vaccine candidates for seasonal influenza and COVID-19 in Phase 2 and avian influenza in Phase 1 clinical development. All candidates are based on CureVac's proprietary second-generation mRNA backbone. Also Read: CureVac, GSK Partner Release Data On Influenza Vaccine Study. GS
Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA) are set for more legal battles over their rival COVID-19 vaccines after London’s High Court delivered a mixed ruling on two of Moderna’s patents. This decision is likely to trigger a series of appeals in the ongoing London litigation. Pfizer and its German partner BioNTech SE (NASDAQ:BNTX) initiated the lawsuit against Moderna in London in September 2022, seeking to revoke two of Moderna’s patents. In response, Moderna accused Pfizer and BioNTech of infringing on its patents. These lawsuits are part of a global legal struggle over messenger RNA (mRNA) technology. Read Next: European Patent Office Sides with Moderna In COVID-19
On Wednesday, the FDA approved Epkinly (epcoritamab-bysp) as the first and only T-cell-engaging bispecific antibody administered subcutaneously for adults with relapsed or refractory follicular lymphoma (r/r F) after two or more lines of prior therapy. Epcoritamab is being co-developed by AbbVie Inc. (NYSE:ABBV) and Genmab A/S (NASDAQ:GMAB) as part of their oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. The indication is approved under the FDA’s Accelerated Approval program based on overall response rate (ORR) and durability of response. Continued approval for this indicat
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineagesDoses will be ready to ship to applicable EU member states immediately upon authorization by the European CommissionPfizer Inc. (NYSE:PFE, "Pfizer"))))) and BioNTech SE (NASDAQ:BNTX, "BioNTech"))))) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for th
In the preceding three months, 12 analysts have released ratings for BioNTech (NASDAQ:BNTX), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 9 1 2 0 0 Last 30D 1 0 0 0 0 1M Ago 5 0 0 0 0 2M Ago 2 1 2 0 0 3M Ago 1 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $110.92, along with a high estimate of $122.00 and a low estimate of $98.00. This current average has dec
HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume NVAX CALL TRADE BEARISH 06/28/24 $15.00 $129.4K 1.0K 2.4K INSM PUT TRADE BULLISH 01/1
MAINZ, Germany, September 05, 2024 – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology ("ESMO") Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech's clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approaches. "We believe that the future of cancer treatment will be driven by the combination of modalities, including immunomodulators, targeted and mRNA-based therapies," said Prof. Özlem Türeci, M.D., Co-
The strategic collaboration will leverage Tempus' large multimodal datasets to enhance BioNTech's next-generation oncology pipeline Tempus AI, Inc. (NASDAQ:TEM, "Tempus"))), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collaboration with BioNTech SE (NASDAQ:BNTX, "BioNTech"))), a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. This collaboration leverages Tempus' robust multimodal datasets in support of BioNTech's next-generation oncology pipeline. Under this collaboration, Tempus is providing analytical support and computational biology expertis
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older The KP.2 adaptation is based on FDA guidance, which stated that KP.2 is the preferred strain for COVID-19 vaccines for the US 2024-2025 fall and winter season, if feasible Shipping will begin immediately to ensure robust supply and rapid access of this season's vaccine in pharmacies, hospitals, and clinics across the country Pfizer Inc. (NYSE:PFE, "Pfizer"))) and BioNTech SE (NASDAQ:BNTX, "BioNTech"))) today announced that the U.S. Food and Drug Administration ("FDA") has approved the supplemental Biologics License Applicat
In a Phase 3 trial, Pfizer and BioNTech's combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives The trial did not meet one of its primary immunogenicity objectives of non-inferiority against the influenza B strain despite obtaining higher influenza A responses and comparable COVID-19 responses versus the comparator vaccines The companies are evaluating adjustments to the candidate and will discuss next steps with health authorities Pfizer also provides update on its separate Phase 2 second-generation trivalent influenza mRNA vaccine trial which showed encouraging data demonstrating robust immunogenicity against all strain
Announced positive data from multiple mRNA cancer vaccine clinical trials, including topline results from the ongoing Phase 2 evaluating FixVac candidate BNT111Launched updated variant-adapted COVID-19 vaccine in the European Union ("EU"), received approval in the United Kingdom and initiated rolling supplemental Biologics Licensing Application ("sBLA") with the United States Food and Drug Administration ("U.S. FDA")Reiterates guidance for total revenues in the range of €2.5-3.1 billionReports second quarter 2024 revenues of €128.7 million, net loss of €807.8 million and loss per share of €3.36 ($3.621)Invested €525.6 million or approximately 90% of the Company's total R&D spend in Q2 in non
Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimabData demonstrated a statistically significant improvement of overall response rate ("ORR") compared to historical control in patients with anti-PD-(L)1 relapsed/refractory advanced melanoma BioNTech and Regeneron plan to present data from this trial at a forthcoming medical conference; the BNT111 program received a Fast Track designation and an Orphan Drug designation from the U.S. Food and Drug Administration ("FDA") in 2021 BNT111 is based on BioNTech's fully owned FixVac platform and proprietary uridine mRNA-LPX technology
MAINZ, Germany, July 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) will announce its financial results for the second quarter 2024 on Monday, August 5, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineagesDoses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission NEW YORK and MAINZ, Germany, June 27, 2024 — Pfizer Inc. (NYSE:PFE, "Pfizer"))) and BioNTech SE (NASDAQ:BNTX, "BioNTech"))) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Age
Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 clinical data from patients with advanced or metastatic solid tumors1,2With the Fast Track designation, the development of BNT324/DB-1311 can benefit from more frequent engagement with the U.S. Food and Drug Administration ("FDA") to support development and expedite regulatory reviewProstate cancer is the second leading cause of cancer-related deaths among men worldwide3 often diagnosed at advanced disease stages; patients with metastatic castration–resistant prostate cancer ("mCRPC"), an advanced
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 3, 2024 /PRNewswire/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins Medicine, up to 80% of patients are diagnosed at advanced stages, which are significantly harder to treat. A new study published in the journal Cell Genomics demonstrates that researchers have identified key protein biomarkers for early detection of pancreatic cancer. Analysts at Towards Healthcare project the pancreatic cancer market to grow at a rate of 13.7% CAGR, hitting US
Announced positive data from multiple mRNA cancer vaccine clinical trials, including topline results from the ongoing Phase 2 evaluating FixVac candidate BNT111Launched updated variant-adapted COVID-19 vaccine in the European Union ("EU"), received approval in the United Kingdom and initiated rolling supplemental Biologics Licensing Application ("sBLA") with the United States Food and Drug Administration ("U.S. FDA")Reiterates guidance for total revenues in the range of €2.5-3.1 billionReports second quarter 2024 revenues of €128.7 million, net loss of €807.8 million and loss per share of €3.36 ($3.621)Invested €525.6 million or approximately 90% of the Company's total R&D spend in Q2 in non
MAINZ, Germany, July 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) will announce its financial results for the second quarter 2024 on Monday, August 5, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-naïve metastatic breast cancer patients, and a second Phase 3 trial with BNT323/DB-1303 in recurrent endometrial cancer planned to start soonPresented clinical data at the American Association for Cancer Research ("AACR") Annual Meeting for individualized and off-the-shelf mRNA-based cancer vaccine candidates based on iNeST and FixVac platforms, including three-year follow-up data of an investigator-initiated trial in patients with resected pancreatic ductal adenocarcinoma ("PDAC")Planning to sh
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available v
Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024Aiming for first oncology launch in 2026 and ten indication approvals by 2030 as part of BioNTech's strategy to develop combinatorial and synergistic therapeutic approachesEntered strategic collaborations with Biotheus, DualityBio, Medilink and OncoC4 to complement clinical oncology pipeline with innovative antibody-drug conjugate (ADC) and immuno-modulatory programsAnnemarie Hanekamp appointed as Chief Commercial Officer effective July 1, 2024Delivered over 400 million COVID-19 vaccine doses worldwide in 2023, including successfully laun
MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast wi
Positive clinical data updates across multiple drug classes including antibody-drug conjugate (ADC) candidates BNT323/DB-1303, BNT325/DB-1305, CAR-T candidate BNT211, T cell therapy candidate BNT221 and mRNA cancer vaccine candidate BNT116Progress across the oncology pipeline with multiple late-stage trials initiated since third quarter startNew and expanded strategic collaborations reflect BioNTech's commitment to delivering transformational therapies for oncology and infectious diseasesSuccessful launches of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine in markets worldwide Updated 2023 COVID-19 vaccine revenue guidance of around €4 billion Guidance reduction of planned 2023 R&D expe
MAINZ, Germany, October 23, 2023 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) will announce its financial results for the third quarter 2023 on Monday, November 6th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter 2023. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a pin will be provided. It is recommended to register at least a day in advance. The slide presentation and audio of the
Significant pipeline advancement highlighted by the initiation of BNT316/ONC-392 Phase 3 pivotal trial and multiple trials planned to start across the oncology portfolioPositive data updates across multiple technology platforms including ADC candidate BNT323/DB-1303, anti-CTLA4 monoclonal antibody candidate BNT316/ONC-392 and CAR-T candidate BNT211 Preparation for launch of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine as recommended by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and other health authorities; deliveries expected to start as early as September, subject to regulatory approvalReiterates COVID-19 vaccine revenue guidance of approximately €5
MAINZ, Germany, July 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) will announce its financial results for the second quarter 2023 on Monday, August 7th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter 2023. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a pin will be provided. It is recommended to register at least a day in advance. The slide presentation and audio of
Deutsche Bank upgraded BioNTech from Hold to Buy and set a new price target of $95.00
HSBC Securities upgraded BioNTech from Hold to Buy
Evercore ISI initiated coverage of BioNTech with a rating of In-line and set a new price target of $100.00
BMO Capital Markets initiated coverage of BioNTech with a rating of Outperform and set a new price target of $127.00
Oppenheimer initiated coverage of BioNTech with a rating of Perform
JP Morgan downgraded BioNTech from Neutral to Underweight and set a new price target of $99.00 from $106.00 previously
HSBC Securities downgraded BioNTech from Buy to Hold and set a new price target of $111.00 from $124.00 previously
HSBC Securities initiated coverage of BioNTech with a rating of Buy and set a new price target of $124.00
Redburn upgraded BioNTech from Neutral to Buy and set a new price target of $170.00 from $165.00 previously
BofA Securities upgraded BioNTech from Neutral to Buy and set a new price target of $239.00